会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Method and device for providing anti-tachyarrhythmia therapy
    • 提供抗快速性心律失常治疗的方法和装置
    • US09084898B2
    • 2015-07-21
    • US13569208
    • 2012-08-08
    • Dan Li
    • Dan Li
    • A61N1/365A61N1/362A61N1/36A61N1/39
    • A61N1/3621A61N1/3605A61N1/36114A61N1/36564A61N1/3962
    • Various system embodiments comprise at least one sensor input adapted to receive at least one sensed signal associated with a tachyarrhythmia, a feature set extractor adapted to extract at least two features from the at least one sensed signal associated with the tachyarrhythmia, a feature set generator adapted to form a feature set using the at least two features extracted by the feature set extractor, at least one generator adapted for use to selectively apply an anti-tachycardia pacing (ATP) therapy and a neural stimulation (NS) therapy, and a controller adapted to respond to the feature set. The controller is adapted to initiate the NS therapy when the feature set corresponds to criteria for applying the NS therapy to modify the tachyarrhythmia, and initiate the ATP therapy to terminate the modified tachyarrhythmia. Other aspects and embodiments are provided herein.
    • 各种系统实施例包括适于接收与快速性心律失常相关联的至少一个感测信号的至少一个传感器输入,适于从与快速性心律失常相关联的至少一个感测信号中提取至少两个特征的特征集提取器,适于 以使用由所述特征集提取器提取的所述至少两个特征来形成特征集合,适于用于选择性地应用抗心动过速起搏(ATP)治疗和神经刺激(NS)治疗)的至少一个发生器,以及适于 以响应功能集。 当特征集合对应于应用NS治疗来修改快速性心律失常的标准时,控制器适于启动NS治疗,并且启动ATP治疗以终止改变的快速性心律失常。 本文提供了其它方面和实施例。
    • 8. 发明授权
    • Method and apparatus for selecting and timing anti-tachyarrhythmia pacing using cardiac signal morphology
    • 用于使用心脏信号形态选择和定时抗快速性心律失调起搏的方法和装置
    • US08855763B2
    • 2014-10-07
    • US13077229
    • 2011-03-31
    • Dan Li
    • Dan Li
    • A61N1/362A61N1/365
    • A61N1/3621A61N1/365
    • A cardiac rhythm management (CRM) system includes an implantable medical device that delivers anti-tachyarrhythmia therapies including ATP. When a tachyarrhythmia episode is detected, the implantable medical device analyzes the morphology of a cardiac signal to determine whether and/or when to deliver an ATP therapy. In various embodiments, the implantable medical device produces morphological parameters indicative of the likeliness of success of the ATP therapy and selects an anti-tachyarrhythmia therapy mode based on the morphological parameters. In various embodiments, the implantable medical device also controls the timing of the ATP therapy delivery using morphological features of the cardiac signal to maximize the probability that the ATP therapy is delivered into an ATP window during which a tachyarrhythmia episode can be effectively terminated by pacing.
    • 心律管理(CRM)系统包括可植入医疗装置,其传递包括ATP在内的抗慢性心律失常治疗。 当检测到快速性心律失常发作时,可植入医疗装置分析心脏信号的形态以确定是否和/或何时递送ATP治疗。 在各种实施例中,可植入医疗装置产生指示ATP治疗成功的可能性的形态学参数,并且基于形态参数选择抗快速性心律失常治疗模式。 在各种实施例中,可植入医疗装置还使用心脏信号的形态学特征来控制ATP治疗递送的时间,以使ATP治疗被递送到ATP窗口的可能性最大化,在此期间可以通过起搏有效地终止快速性心律失常发作。
    • 9. 发明授权
    • Hemodynamic status assessment during tachycardia
    • 心动过速时的血液动力学状态评估
    • US08838240B2
    • 2014-09-16
    • US12283234
    • 2008-09-10
    • Dan LiKrzysztof SiejkoAbhilash Patangay
    • Dan LiKrzysztof SiejkoAbhilash Patangay
    • A61N1/36A61N1/368A61B5/0464A61N1/365
    • A61N1/36585A61N1/36521A61N1/36564A61N1/36578
    • Systems and methods provide for sensing, during an event of tachycardia, hemodynamic signals concurrently from at least two spatially separated locations within a patient, and quantifying a spatial relationship between the hemodynamic signals. Hemodynamic stability or state of the patient during the tachycardia event is determined based at least in part on the quantified spatial relationship. One or more anti-tachycardia therapies to treat the tachycardia may be selected based at least in part on the determined stability or state of patient hemodynamics, and the selected one or more anti-tachycardia therapies may be delivered to treat the tachycardia. The hemodynamic signals may comprise at least two, or a mixed combination, of cardiac impedance signals, cardiac chamber pressure signals, arterial pressure signals, heart sounds; and acceleration signals.
    • 系统和方法提供在心动过速事件期间从患者内的至少两个空间上分离的位置同时感测血液动力学信号,并且量化血液动力学信号之间的空间关系。 至少部分地基于定量的空间关系确定在心动过速事件期间患者的血流动力学稳定性或状态。 可以至少部分地基于所确定的患者血液动力学的稳定性或状态来选择治疗心动过速的一种或多种抗心动过速疗法,并且可以递送所选择的一种或多种抗心动过速疗法以治疗心动过速。 血液动力学信号可以包括心脏阻抗信号,心室压力信号,动脉压信号,心音的至少两个或混合组合; 和加速度信号。
    • 10. 发明授权
    • Method and apparatus for closed-loop control of anti-tachyarrhythmia pacing using hemodynamic sensor
    • 使用血液动力学传感器闭合控制抗心律失常起搏的方法和装置
    • US08712525B2
    • 2014-04-29
    • US12877583
    • 2010-09-08
    • Dan LiCheng Zhang
    • Dan LiCheng Zhang
    • A61N1/362
    • A61N1/3622A61N1/3712
    • A cardiac rhythm management (CRM) system includes an implantable medical device that delivers anti-tachyarrhythmia therapies including anti-tachyarrhythmia pacing (ATP) and a hemodynamic sensor that senses a hemodynamic signal. The implantable medical device includes a hemodynamic sensor-controlled closed-loop ATP system that uses the hemodynamic signal for ATP capture verification. When ATP pulses are delivered according to a selected ATP protocol to terminate a tachyarrhythmia episode, the implantable medical device performs the ATP capture verification by detecting an effective cardiac contraction from the hemodynamic signal. The ATP protocol is adjusted using an outcome of the ATP capture verification.
    • 心律管理(CRM)系统包括可植入的医疗装置,其传递抗心律失常疗法,包括抗心动过速起搏(ATP)和感测血液动力学信号的血液动力学传感器。 可植入医疗装置包括血液动力学传感器控制的闭环ATP系统,其使用血流动力学信号进行ATP捕获验证。 当根据选定的ATP方案递送ATP脉冲以终止快速性心律失常发作时,可植入医疗装置通过从血液动力学信号检测有效的心脏收缩来执行ATP捕获验证。 使用ATP捕获验证的结果调整ATP方案。